Stay updated on Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Sign up to get notified when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.

Latest updates to the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe new screenshot shows minor UI/layout refinements to the Record History page with no changes to study data, status, or version history content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check42 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference10%

- Check49 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.2%

- Check64 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed. No core content, pricing, stock, or time-slot information was affected.SummaryDifference0.6%

- Check71 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.6%

- Check78 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, while also removing specific location details such as state, country, and city information.SummaryDifference37%

Stay in the know with updates to Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bosutinib + Inotuzumab in CD22+ ALL/CML Clinical Trial page.